Advertisement

AIDS and Behavior

, Volume 22, Issue 6, pp 2026–2032 | Cite as

Baseline Cigarette Smoking Status as a Predictor of Virologic Suppression and CD4 Cell Count During One-Year Follow-Up in Substance Users with Uncontrolled HIV Infection

  • Theresa Winhusen
  • Daniel J. Feaster
  • Rui Duan
  • Jennifer L. Brown
  • Eric S. Daar
  • Raul Mandler
  • Lisa R. Metsch
Original Paper

Abstract

Cigarette smoking is prevalent in people living with HIV/AIDS (PLHIV) who abuse alcohol and/or illicit substances. This study evaluated whether smoking is predictive of virologic non-suppression (> 200 copies/mL) and low CD4 count (< 200 cells/mm3) during 1-year follow-up in medically hospitalized, substance-using PLHIV recruited for a multi-site trial. Smoking status was assessed with the Heaviness of Smoking Index (HSI). Analyses revealed that, controlling for baseline differences and adherence to antiretroviral therapy, non-smokers (n = 237), compared to smokers scoring in the medium-to-high range on the HSI (n = 386), were significantly more likely to achieve viral suppression (OR 1.50, 95% CI 1.02, 2.20). There was a significant smoking-by-time interaction for CD4 cell count (χ2(1) = 4.08, p < .05), with smokers less likely to have low CD4 count at baseline and 6-month follow-up, but more likely to have low CD4 count at 12-month follow-up. The results suggest that smoking may play a role in immunological functioning in HIV-infected substance users. ClinicalTrials.gov Identifier: NCT01612169.

Keywords

Tobacco HIV Substance abuse Virologic suppression 

Notes

Acknowledgements

Funding for the parent trial and analysis was provided for the study’s principal investigators by the National Institute on Drug Abuse under the following awards: U10DA013720 and UG1DA013720 (Drs. José Szapocznik and Lisa R. Metsch); U10DA013035 and UG1DA013035 (Drs. John Rotrosen and Edward V. Nunes, Jr.); U10DA013034 and UG1DA013034 (Drs. Maxine Stitzer and Robert Schwartz); U10DA013727 and UG1DA013727 (Drs. Kathleen T. Brady and Matthew Carpenter); U10DA020024 and UG1DA020024 (Dr. Madhukar H. Trivedi); U10DA013732, UG1DA013732, and 5UG1DA013732 (Dr. Theresa Winhusen); U10DA015831 and UG1DA015831 (Drs. Roger D. Weiss and Kathleen Carroll); U10DA015815 and UG1DA015815 (Drs. James L. Sorensen and Dennis McCarty); U10DA020036 (Dr. Dennis Daley); U10DA013043 (Dr. George Woody); U10DA013045 (Dr. Walter Ling); HHSN271200900034C/N01DA92217 and HHSN271201400028C/N01DA142237 (Dr. Paul VanVeldhuisen); and HHSN271201000024C/N01DA102221 (Dr. Robert Lindblad). Support from the University of Miami Center for AIDS Research (CFAR) (P30AI073961; Dr. Savita Pahwa), the Emory University CFAR (P30AI050409; Drs. Carlos del Rio, James W. Curran, and Eric Hunter), the Atlanta Clinical and Translational Science Institute (UL1TR000454; Dr. David Stephens), and the HIV Center for Clinical and Behavioral Studies at the New York State Psychiatric Institute/Columbia University Medical Center (P30MH043520; Dr. Robert Remien) is also acknowledged. The National Institute on Drug Abuse (NIDA) had no further role in study design or in the collection, analysis and interpretation of data. NIDA Center for the Clinical Trials Network (CCTN) personnel contributed to the design of the original study and CCTN contractors played a role in the collection and analysis of data from the original study. NIDA had no further role in the design of this analysis, in the manuscript writing of the report, or in the decision to submit the paper for publication.

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Duval X, Baron G, Garelik D, et al. Living with HIV, antiretroviral treatment experience and tobacco smoking: results from a multisite cross-sectional study. Antivir Ther. 2008;13(3):389–97.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Burkhalter JE, Springer CM, Chhabra R, Ostroff JS, Rapkin BD. Tobacco use and readiness to quit smoking in low-income HIV-infected persons. Nicotine Tob Res. 2005;7(4):511–22.CrossRefPubMedGoogle Scholar
  3. 3.
    Pacek LR, Latkin C, Crum RM, Stuart EA, Knowlton AR. Current cigarette smoking among HIV-positive current and former drug users: associations with individual and social characteristics. AIDS Behav. 2014;18(7):1368–77.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Hile SJ, Feldman MB, Alexy ER, Irvine MK. Recent tobacco smoking is associated with poor HIV medical outcomes among HIV-infected individuals in New York. AIDS Behav. 2016;20(8):1722–9.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Feldman JG, Minkoff H, Schneider MF, et al. Association of cigarette smoking with HIV prognosis among women in the HAART era: a report from the women’s interagency HIV study. Am J Public Health. 2006;96(6):1060–5.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Miguez-Burbano MJ, Burbano X, Ashkin D, Pitchenik A, Allan R, Pineda L, et al. Impact of tobacco use on the development of opportunistic respiratory infections in HIV seropositive patients on antiretroviral therapy. Addict Biol. 2003;8(1):39–43.CrossRefPubMedGoogle Scholar
  7. 7.
    Wojna V, Robles L, Skolasky RL, Mayo R, Selnes O, de la Torre T, et al. Associations of cigarette smoking with viral immune and cognitive function in human immunodeficiency virus-seropositive women. ≅. 2007;13(6):561–8.Google Scholar
  8. 8.
    Gritz ER, Vidrine DJ, Lazev AB, Amick BC 3rd, Arduino RC. Smoking behavior in a low-income multiethnic HIV/AIDS population. Nicotine Tob Res. 2004;6(1):71–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Kabali C, Cheng DM, Brooks DR, Bridden C, Horsburgh CR, Samet JH. Recent cigarette smoking and HIV disease progression: no evidence of an association. AIDS Care. 2011;23(8):947–56.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Rao P, Ande A, Sinha N, Kumar A, Kumar S. Effects of cigarette smoke condensate on oxidative stress, apoptotic cell death, and HIV replication in human monocytic cells. PLoS ONE. 2016;11(5):e0155791.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Masia M, Padilla S, Fernandez M, et al. Oxidative stress predicts all-cause mortality in HIV-infected patients. PLoS ONE. 2016;11(4):e0153456.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Ande A, McArthur C, Ayuk L, et al. Effect of mild-to-moderate smoking on viral load, cytokines, oxidative stress, and cytochrome P450 enzymes in HIV-infected individuals. PLoS ONE. 2015;10(4):e0122402.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Ande A, McArthur C, Kumar A, Kumar S. Tobacco smoking effect on HIV-1 pathogenesis: role of cytochrome P450 isozymes. Expert Opin Drug Metab Toxicol. 2013;9(11):1453–64.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Webb MS, Vanable PA, Carey MP, Blair DC. Cigarette smoking among HIV+ men and women: examining health, substance use, and psychosocial correlates across the smoking spectrum. J Behav Med. 2007;30(5):371–83.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Shuter J, Bernstein SL. Cigarette smoking is an independent predictor of nonadherence in HIV-infected individuals receiving highly active antiretroviral therapy. ±. 2008;10(4):731–6.PubMedGoogle Scholar
  16. 16.
    Atluri VS. Editorial: HIV and illicit drugs of abuse. Front Microbiol. 2016;7:221.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Roy S, Ninkovic J, Banerjee S, et al. Opioid drug abuse and modulation of immune function: consequences in the susceptibility to opportunistic infections. J Nneuroimmune Pharmacol. 2011;6(4):442–65.CrossRefGoogle Scholar
  18. 18.
    Wang X, Ma TC, Li JL, et al. Heroin inhibits HIV-restriction miRNAs and enhances HIV infection of macrophages. Front Microbiol. 2015;6:1230.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Swepson C, Ranjan A, Balasubramaniam M, Pandhare J, Dash C. Cocaine enhances HIV-1 transcription in macrophages by inducing p38 MAPK phosphorylation. Front Microbiol. 2016;7:823.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Dash S, Balasubramaniam M, Villalta F, Dash C, Pandhare J. Impact of cocaine abuse on HIV pathogenesis. Front Microbiol. 2015;6:1111.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Williams EC, Hahn JA, Saitz R, Bryant K, Lira MC, Samet JH. Alcohol use and human immunodeficiency virus (HIV) infection: current knowledge, implications, and future directions. Alcohol Clin Exp Res. 2016;40(10):2056–72.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Baum MK, Rafie C, Lai S, Sales S, Page JB, Campa A. Alcohol use accelerates HIV disease progression. AIDS Res Hum Retroviruses. 2010;26(5):511–8.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Humfleet GL, Delucchi K, Kelley K, Hall SM, Dilley J, Harrison G. Characteristics of HIV-positive cigarette smokers: a sample of smokers facing multiple challenges. AIDS Educ Prev. 2009;21(3 Suppl):54–64.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Metsch LR, Feaster DJ, Gooden L, et al. Effect of patient navigation with or without financial incentives on viral suppression among hospitalized patients with HIV infection and substance use: a randomized clinical trial. JAMA. 2016;316(2):156–70.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Bush K, Kivlahan DR, Donell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol use disorders identification test. Arch Int Med. 1998;158(16):1789–95.CrossRefGoogle Scholar
  26. 26.
    Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom tolerance questionnaire. Br J Addict. 1991;86(9):1119–27.CrossRefPubMedGoogle Scholar
  27. 27.
    Kozlowski LT, Porter CQ, Orleans CT, Pope MA, Heatherton T. Predicting smoking cessation with self-reported measures of nicotine dependence: FTQ, FTND, and HSI. Drug Alcohol Depend. 1994;34(3):211–6.CrossRefPubMedGoogle Scholar
  28. 28.
    Reynolds NR, Sun J, Nagaraja HN, Gifford AL, Wu AW, Chesney MA. Optimizing measurement of self-reported adherence with the ACTG adherence questionnaire: a cross-protocol analysis. J Acquir Immune Defic Syndr. 2007;46(4):402–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Lellan AT, Kushner H, Metzger D, et al. The fifth edition of the Addiction Severity Index. J Subst Abuse Treat. 1992;9(3):199–213.CrossRefGoogle Scholar
  30. 30.
    McLellan AT, Luborsky L, Woody GE, O’Brien CP. An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. J Nerv Ment Dis. 1980;168(1):26–33.CrossRefPubMedGoogle Scholar
  31. 31.
    Brown JL, Winhusen T, DiClemente RJ, et al. The association between cigarette smoking, virologic suppression, and CD4+ lymphocyte count in HIV-infected Russian women. AIDS Care. 2017;29(9):1102–6.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Gordin FM, Roediger MP, Girard PM, et al. Pneumonia in HIV-infected persons: increased risk with cigarette smoking and treatment interruption. Am J Respir Crit Care Med. 2008;178(6):630–6.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Lifson AR, Neuhaus J, Arribas JR, et al. Smoking-related health risks among persons with HIV in the strategies for management of antiretroviral therapy clinical trial. Am J Public Health. 2010;100(10):1896–903.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Pines H, Koutsky L, Buskin S. Cigarette smoking and mortality among HIV-infected individuals in Seattle, Washington (1996-2008). AIDS Behav. 2011;15(1):243–51.CrossRefPubMedGoogle Scholar
  35. 35.
    Rahmanian S, Wewers ME, Koletar S, Reynolds N, Ferketich A, Diaz P. Cigarette smoking in the HIV-infected population. Proc Am Thorac Soc. 2011;8(3):313–9.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Crothers K, Griffith TA, McGinnis KA, et al. The impact of cigarette smoking on mortality, quality of life, and comorbid illness among HIV-positive veterans. J Gen Intern Med. 2005;20(12):1142–5.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Helleberg M, Afzal S, Kronborg G, et al. Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study. Clin Infect Dis. 2013;56(5):727–34.CrossRefPubMedGoogle Scholar
  38. 38.
    Colado Simao AN, Victorino VJ, Morimoto HK, Reiche EM, Panis C. Redox-driven events in the human immunodeficiency virus type 1 (HIV-1) infection and their clinical implications. Curr HIV Res. 2015;13(2):143–50.CrossRefPubMedGoogle Scholar
  39. 39.
    Porter KM, Sutliff RL. HIV-1, reactive oxygen species, and vascular complications. Free Radic Biol Med. 2012;53(1):143–59.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Suresh DR, Annam V, Pratibha K, Prasad BV. Total antioxidant capacity—a novel early bio-chemical marker of oxidative stress in HIV infected individuals. J Biomed Sci. 2009;16:61.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Sharma B. Oxidative stress in HIV patients receiving antiretroviral therapy. Curr HIV Res. 2014;12(1):13–21.CrossRefPubMedGoogle Scholar
  42. 42.
    Reilly M, Delanty N, Lawson JA, FitzGerald GA. Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation. 1996;94(1):19–25.CrossRefPubMedGoogle Scholar
  43. 43.
    Pilz H, Oguogho A, Chehne F, Lupattelli G, Palumbo B, Sinzinger H. Quitting cigarette smoking results in a fast improvement of in vivo oxidation injury (determined via plasma, serum and urinary isoprostane). Thromb Res. 2000;99(3):209–21.CrossRefPubMedGoogle Scholar
  44. 44.
    Chehne F, Oguogho A, Lupattelli G, Palumbo B, Sinzinger H. Effect of giving up cigarette smoking and restarting in patients with clinically manifested atherosclerosis. Prostaglandins Leukot Essent Fatty Acids. 2002;67(5):333–9.CrossRefPubMedGoogle Scholar
  45. 45.
    Morrow JD, Frei B, Longmire AW, et al. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med. 1995;332(18):1198–203.CrossRefPubMedGoogle Scholar
  46. 46.
    Tesoriero JM, Gieryic SM, Carrascal A, Lavigne HE. Smoking among HIV positive New Yorkers: prevalence, frequency, and opportunities for cessation. AIDS Behav. 2010;14(4):824–35.CrossRefPubMedGoogle Scholar
  47. 47.
    Kalman D, Morissette SB, George TP. Co-morbidity of smoking in patients with psychiatric and substance use disorders. Am J Addict. 2005;14(2):106–23.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Winhusen T. Introduction to special issue on tobacco and other substance use disorders: links and implications. Am J Drug Alcohol Abuse. 2017;43(2):129–31.CrossRefPubMedGoogle Scholar
  49. 49.
    Knudsen HK. Implementation of smoking cessation treatment in substance use disorder treatment settings: a review. Am J Drug Alcohol Abuse. 2017;43(2):215–25.CrossRefPubMedGoogle Scholar
  50. 50.
    Ledgerwood DM, Yskes R. Smoking cessation for people living with HIV/AIDS: a literature review and synthesis. Nicotine Tob Res. 2016;18(12):2177–84.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  • Theresa Winhusen
    • 1
  • Daniel J. Feaster
    • 2
  • Rui Duan
    • 2
  • Jennifer L. Brown
    • 1
  • Eric S. Daar
    • 3
  • Raul Mandler
    • 4
  • Lisa R. Metsch
    • 5
  1. 1.Addiction Sciences Division, Department of Psychiatry and Behavioral NeuroscienceUniversity of Cincinnati College of MedicineCincinnatiUSA
  2. 2.Department of Public Health Sciences, Miller School of MedicineUniversity of MiamiMiamiUSA
  3. 3.Los Angeles Biomedical Research Institute at HarborUniversity of California Los Angeles Medical CenterTorranceUSA
  4. 4.Center for the Clinical Trials Network, National Institute on Drug AbuseNational Institutes of HealthBethesdaUSA
  5. 5.Department of Sociomedical Sciences, Mailman School of Public HealthColumbia UniversityNew YorkUSA

Personalised recommendations